1. TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca2+
- Author
-
Charlotte J. Sumner, Mark N. Wu, Pamela C. Saavedra-Rivera, Jeremy M. Sullivan, Douglas N. Robinson, Kendra Takle Ruppell, Brian M. Woolums, Alexander R. Lau, Thomas E. Lloyd, Catherine Mamah, Brett A. McCray, Masashi Tabuchi, Yunpeng Yang, Hyun Sung, William H. Aisenberg, Yang Xiang, and Bryan S. Larin
- Subjects
0301 basic medicine ,TRPV4 ,Science ,General Physics and Astronomy ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Transient receptor potential channel ,0302 clinical medicine ,Ca2+/calmodulin-dependent protein kinase ,medicine ,lcsh:Science ,Mitochondrial transport ,Multidisciplinary ,Chemistry ,Neurodegeneration ,Neurotoxicity ,General Chemistry ,medicine.disease ,Cell biology ,030104 developmental biology ,nervous system ,Axoplasmic transport ,lcsh:Q ,030217 neurology & neurosurgery ,Intracellular - Abstract
The cation channel transient receptor potential vanilloid 4 (TRPV4) is one of the few identified ion channels that can directly cause inherited neurodegeneration syndromes, but the molecular mechanisms are unknown. Here, we show that in vivo expression of a neuropathy-causing TRPV4 mutant (TRPV4R269C) causes dose-dependent neuronal dysfunction and axonal degeneration, which are rescued by genetic or pharmacological blockade of TRPV4 channel activity. TRPV4R269C triggers increased intracellular Ca2+ through a Ca2+/calmodulin-dependent protein kinase II (CaMKII)-mediated mechanism, and CaMKII inhibition prevents both increased intracellular Ca2+ and neurotoxicity in Drosophila and cultured primary mouse neurons. Importantly, TRPV4 activity impairs axonal mitochondrial transport, and TRPV4-mediated neurotoxicity is modulated by the Ca2+-binding mitochondrial GTPase Miro. Our data highlight an integral role for CaMKII in neuronal TRPV4-associated Ca2+ responses, the importance of tightly regulated Ca2+ dynamics for mitochondrial axonal transport, and the therapeutic promise of TRPV4 antagonists for patients with TRPV4-related neurodegenerative diseases.
- Published
- 2020
- Full Text
- View/download PDF